CD22 expression on blastic plasmacytoid dendritic cell neoplasms and reactivity of anti‐CD22 antibodies to peripheral blood dendritic cells

Reineks, Edmunds Z.; Osei, Ebenezer; Rosenberg, Arlene S.; Auletta, Jeffery J.; Meyerson, Howard

doi:10.1002/cyto.b.20469

Cited by 51 publications

(40 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It should also be noted that we observed CD22 cell surface expression on DCs and macrophages which has also been reported by others [35]. Therefore, these cell subsets could be affected by on-target off-tumor toxicity of CD22-specific mAbs or CAR-engineered T-cells.…”

Section: Discussionsupporting

confidence: 86%

A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer

et al. 2016

View full text Add to dashboard Cite

CD22 is currently evaluated as a target-antigen for the treatment of B-cell malignancies using chimeric antigen receptor (CAR)-engineered T-cells or monoclonal antibodies (mAbs). CAR- and mAbs-based immunotherapies have been successfully applied targeting other antigens, however, occurrence of refractory disease to these interventions urges the identification of additional strategies. Here, we identified a TCR recognizing the CD22-derived peptide RPFPPHIQL (CD22RPF) presented in human leukocyte antigen (HLA)-B*07:02. To overcome tolerance to self-antigens such as CD22, we exploited the immunogenicity of allogeneic HLA. CD22RPF-specific T-cell clone 9D4 was isolated from a healthy HLA-B*07:02neg individual, efficiently produced cytokines upon stimulation with primary acute lymphoblastic leukemia and healthy B-cells, but did not react towards healthy hematopoietic and nonhematopoietic cell subsets, including dendritic cells (DCs) and macrophages expressing low levels of CD22. Gene transfer of TCR-9D4 installed potent CD22-specificity onto recipient CD8+ T-cells that recognized and lysed primary B-cell leukemia. TCR-transduced T-cells spared healthy CD22neg hematopoietic cell subsets but weakly lysed CD22low-expressing DCs and macrophages. CD22-specific TCR-engineered T-cells could form an additional immunotherapeutic strategy with a complementary role to CAR- and antibody-based interventions in the treatment of B-cell malignancies. However, CD22 expression on non-B-cells may limit the attractiveness of CD22 as target-antigen in cellular immunotherapy.

show abstract

Section: Discussionsupporting

confidence: 86%

A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Cota et al described cases with negativity of CD4, CD56, CD123, TCL-1 (11). Co-expression of CD33, CD7, CD2, CD117, CD22 was reported in several cases (17)(18)(19). In our patient, the immunophenotype of the blast cells from the BM aspirates show the antigen profile described for BPDCN except CD36 that was negative and CD11b and CD2 that were partially positive.…”

Section: Discussionsupporting

confidence: 65%

Blastic plasmacytoid dendritic cell neoplasia - a rare type of acute leukemia

Köpeczi¹,

Benedek²,

Kakucs³

et al. 2014

Romanian Review of Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…haematologica | 2010; 95(11) 1,4,20,23,30 The vast majority of adult patients who achieve complete remission subsequently relapse at a median of 9 -11 months, according to the largest studies. 1,2 Those patients who relapse typically develop rapid dissemination of disease to bone marrow and other sites, with central nervous system involvement in 33% of relapsed cases.…”

mentioning

confidence: 99%

Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications

Jegalian¹,

Buxbaum²,

Facchetti³

et al. 2010

Haematologica

148

198

View full text Add to dashboard Cite

The online version of this article has a Supplementary Appendix. BackgroundBlastic plasmacytoid dendritic cell neoplasm is a rare malignancy that typically follows a highly aggressive clinical course in adults, whereas experience in children with this disease is very limited. Design and MethodsThis retrospective study analyzed the pathological and clinical findings of nine cases of blastic plasmactyoid dendritic cell neoplasm presenting in patients under the age of 18 years who were reviewed at our institution. We also identified 20 well-documented additional pediatric cases in the literature. ResultsIn the combined analysis, the overall survival rate among the 25 patients with available followup, all having received chemotherapy, was 72% (follow-up ranging from 9 months to 13 years, with a median of 30 months). The event-free survival rate was 64%. Nine patients were alive 5 years after the original diagnosis, although only three of them had undergone hematopoietic stem cell transplantation -one in first complete remission and two in second remission. Of the seven patients who lacked cutaneous disease at presentation, 100% survived, including five who were alive more than 5 years after diagnosis, although only two had undergone stem cell transplantation. Among the 18 patients who presented with cutaneous disease and for whom follow-up data were available, only 11 survived (61%). Detailed immunophenotypic characterization and clinical features of all cases are presented. Unexpectedly, three of four cases of blastic plasmacytoid dendritic cell neoplasm tested showed focal positivity for S-100. S-100 was negative in 28 cases of acute myeloid leukemia evaluated for this marker. ConclusionsIn contrast to adult cases, in which long-term survival depends on stem cell transplantation in first complete remission, blastic plasmacytoid dendritic cell neoplasms in children are clinically less aggressive. Treatment with high-risk acute lymphoblastic leukemia-type chemotherapy appears to be effective, and stem cell transplantation may be reserved for children who relapse and achieve a second remission. Outcomes were more favorable in cases that lacked cutaneous disease at presentation, although a comparison of cutaneous and non-cutaneous cases might be confounded by differences in treatment regimens. Focal expression of S-100 may be seen in concert with other markers of plasmacytoid dendritic cells.Key words: blastic plasmacytoid dendritic cell neoplasm, CD4 + /CD56 + hematodermic neoplasm, pediatric, acute myeloid leukemia, acute lymphoblastic leukemia, stem cell transplant, S-100, immunophenotyping, dendritic cells.Citation: Jegalian AG, Buxbaum NP, Facchetti F, Raffeld M, Pittaluga S, Wayne AS, and Jaffe ES. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica 2010;95(11):1873-1879 doi:10.3324/haematol.2010

show abstract

CD22 expression on blastic plasmacytoid dendritic cell neoplasms and reactivity of anti‐CD22 antibodies to peripheral blood dendritic cells

Cited by 51 publications

References 48 publications

A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer

A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer

Blastic plasmacytoid dendritic cell neoplasia - a rare type of acute leukemia

Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications

Contact Info

Product

Resources

About